- Genmab A/S (OTCPK:GMXAY) announces that licensor Janssen-Cilag (JNJ -0.4%) has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency seeking approval for daratumumab for the treatment of patients with multiple myeloma who have received at least three different lines of therapy.
- The submission triggers a US$10M milestone payment to Genmab from Janssen. Genmab licensed daratumumab to Janssen in August 2012.